About 10 results found for searched term "DL-AP3" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3598 | Penicillamine | Cuproptosis |
| DL-beta-Mercaptovaline, 3,3-Dimethyl-DL-cysteine, 3-Sulfanylvaline, Cuprimine, Depen, DL-PenA | ||
| Penicillamine is used as an antirheumatic and as a chelating agent in Wilson’s disease. | ||
| M6677 | DL-AP3 | Others |
| DL-AP3 is a group I mGlu antagonist. | ||
| M56678 | DL-AP3 | Metabolite/Endogenous Metabolite |
| DL-AP3 is a competitive mGluR1 and mGluR5 antagonist. | ||
| M10690 | Sulanemadlin | p53 |
| ALRN-6924; MP-4897 | ||
| Sulanemadlin (ALRN-6924) is a stapled peptide that blocks interactions between p53 and both MDM2 and MDMX. | ||
| M10781 | Alrizomadlin | Mdm2 |
| APG-115; AA-115 | ||
| Alrizomadlin (APG-115) is an oral active small molecule MDM2 protein inhibitor that binds to MDM2 protein.IC50 value and Ki The values are 3.8 nM and 1 nM, respectively. Alrizomadlin blocks MDM2 interaction with p53 and induces cell cycle arrest and apoptosis in a p53-dependent manner. | ||
| M25077 | Tarlatamab | Notch |
| AMG-757 | ||
| Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research. | ||
| M29751 | RMS-07 | Mps1/TTK |
| RMS-07 is a covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor, with an apparent IC50 of 13.1 nM. RMS-07 targets a poorly conserved cysteine in the kinase's hinge region. | ||
| M30111 | ABT-100 | Farnesyl Transferase |
| ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity. | ||
| M30383 | JLK-6 | Amyloid |
| JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor. | ||
| M30678 | MK-0731 | Kinesin |
| MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
